Morgan Stanley notes that PTC Therapeutics disclosed during a fireside chat at the Morgan Stanley Healthcare Conference that the FDA requested additional information for the Translarna NDA resubmission, adding that the firm was “surprised by the stock reaction on PTCT shares” as the firm, and most investors the analyst has spoken with in recent months, have been ascribing minimal value to Translarna in the U.S. given relatively low expectations for potential approval. The firm, which argues that a request for additional analyses without a refuse-to-file suggests the FDA is still willing to review the application, so it views the selloff as “not warranted” and keeps an Equal Weight rating and $32 price target on PTC shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics initiated with an Outperform at Baird
- ClearPoint Neuro price target raised to $15 from $11 at Lake Street
- Boeing’s Starliner to return without astronauts: Morning Buzz
- Kymera upgraded, MoonLake downgraded: Wall Street’s top analyst calls
- PTC Therapeutics resumed with Buy from Neutral at UBS